IL-1βR-dependent priming of antitumor CD4+ T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  Kuhn, Sabine ^a,b   Yang, Jianping ^a   Hyde, Evelyn J ^a   Harper, Jacquie L ^a   Kirman, Joanna R ^a,c   Ronchese, Franca ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CD4+ T cells; IL 1 ; monosodium urate crystals; mycobacteria; PD 1; poly I:C; regulatory T cells; tumor immunotherapy

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; URATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNE RESPONSE; MOUSE; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 84940703685     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1042199     Document Type: Article

References (50)

1. H.J.Kim, H.Cantor. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2014; 2:91-8; PMID:24778273; http://dx.doi.org/10.1158/2326-6066.CIR-13-0216
2. S.E.Church, S.M.Jensen, P.A.Antony, N.P.Restifo, B.A.Fox. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 2014; 44:69-79; PMID: 24114780; http://dx.doi.org/10.1002/eji.201343718
3. E.H.J.G.Aarntzen, I.J.M.de Vries, W.J.Lesterhuis, D.Schuurhuis, J.F.M.Jacobs, K.Bol, G.Schreibelt, R.Mus, J.H.W.De Wilt, J.B.A.G.Haanen et al. Targeting CD4+ T helper cells improves the induction of anti-tumor responses in dendritic cell based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127
4. F.Ossendorp, E.Mengedé, M.Camps, R.Filius, C.J.Melief. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187:693-702; PMID: 9480979; http://dx.doi.org/10.1084/jem.187.5.693
5. S.B.J.Wong, R.Bos, L.A.Sherman. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180:3122-31; PMID: 18292535; http://dx.doi.org/10.4049/jimmunol.180.5.3122
6. A.L.Marzo, B.F.Kinnear, R.A.Lake, J.J.Frelinger, E.J.Collins, B.W.Robinson, B.Scott. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047-55; PMID:11086036; http://dx.doi.org/10.4049/jimmunol.165.11.6047
7. A.O.Kamphorst, R.Ahmed. CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy 2013; 5:975-87; PMID:23998732; http://dx.doi.org/10.2217/imt.13.91
8. S.A.Quezada, T.R.Simpson, K.S.Peggs, T.Merghoub, J.Vider, X.Fan, R.Blasberg, H.Yagita, P.Muranski, P.A.Antony et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID: 20156971; http://dx.doi.org/10.1084/jem.20091918
9. K.Hung, R.Hayashi, A.Lafond-Walker, C.Lowenstein, D.Pardoll, H.Levitsky. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188:2357-68; PMID: 9858522; http://dx.doi.org/10.1084/jem.188.12.2357
10. Z.Qin, T.Blankenstein. CD4+ T cell–mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12:677-86; PMID:10894167; http://dx.doi.org/10.1016/S1074-7613(00)80218-6
11. A.J.Currie, R.G.van der Most, S.A.Broomfield, A.C.Prosser, M.G.Tovey, B.W.S.Robinson. Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 2008:1535-44; PMID: 18209049; http://dx.doi.org/10.4049/jimmunol.180.3.1535
12. Y.Kawarada, R.Ganss, N.Garbi, T.Sacher, B.Arnold, G.J.Hämmerling. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167:5247-53; PMID: 11673539; http://dx.doi.org/10.4049/jimmunol.167.9.5247
13. S.A.Broomfield, R.G.van der Most, A.C.Prosser, S.Mahendran, M.G.Tovey, M.J.Smyth, B.W.S.Robinson, A.J.Currie. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009; 182:5217-24; PMID: 19380767; http://dx.doi.org/10.4049/jimmunol.0803826
14. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
15. M.Escamilla-Tilch, G.Filio-Rodríguez, R.García-Rocha, I.Mancilla-Herrera, N.A.Mitchison, J.A.Ruiz-Pacheco, F.J.Sánchez-García, D.Sandoval-Borrego, E.A.Vázquez-Sánchez. The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer? Immunol Cell Biol 2013; 91:601-10; PMID: 24100386; http://dx.doi.org/10.1038/icb.2013.58
16. S.Kuhn, E.J.Hyde, J.Yang, F.J.Rich, J.L.Harper, J.R.Kirman, F.Ronchese. Increased Numbers of Monocyte-Derived Dendritic Cells during Successful Tumor Immunotherapy with Immune-Activating Agents. J Immunol 2013; 191:1984-92; PMID: 23858033; http://dx.doi.org/10.4049/jimmunol.1301135
17. P.Stoitzner, L.K.Green, J.Y.Jung, K.M.Price, H.Atarea, B.Kivell, F.Ronchese. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother 2008; 57:1665-73; PMID: 18311487; http://dx.doi.org/10.1007/s00262-008-0487-4
18. K.A.Pape, A.Khoruts, A.Mondino, M.K.Jenkins. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 1997; 159:591-8; PMID: 9218573.
19. H.Ataera, E.Hyde, K.M.Price, P.Stoitzner, F.Ronchese. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS ONE 2011; PMID: 21390236; 6:e17515; http://dx.doi.org/10.1371/journal.pone.0017515
20. M.Y.Gerner, K.A.Casey, M.F.Mescher. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 2008; 181:155-64; PMID:18566380; http://dx.doi.org/10.4049/jimmunol.181.1.155
21. O.Björkdahl, M.Dohlsten, H.O.Sjögren. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Cancer Gene Ther 2000; 7:1365-74; PMID: 11059695; http://dx.doi.org/10.1038/sj.cgt.0242
22. F.Ghiringhelli, L.Apetoh, A.Tesniere, L.Aymeric, Y.Ma, C.Ortiz, K.Vermaelen, T.Panaretakis, G.Mignot, E.Ullrich et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID: 19767732; http://dx.doi.org/10.1038/nm.2028
23. A.Khoruts, R.E.Osness, M.K.Jenkins. IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. Eur J Immunol 2004; 34:1085-90; PMID:15048719; http://dx.doi.org/10.1002/eji.200324170
24. S.Z.Ben-Sasson, J.Hu-Li, J.Quiel, S.Cauchetaux, M.Ratner, I.Shapira, C.A.Dinarello, W.E.Paul. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009; 106:7119-24; PMID:19359475; http://dx.doi.org/10.1073/pnas.0902745106
25. D.Schenten, S.A.Nish, S.Yu, X.Yan, H.K.Lee, I.Brodsky, L.Pasman, B.Yordy, F.T.Wunderlich, J.C.Brüning et al. Signaling through the Adaptor Molecule MyD88 in CD4(+) T Cells Is Required to Overcome Suppression by Regulatory T Cells. Immunity 2014; 40:78-90; PMID: 24439266; http://dx.doi.org/10.1016/j.immuni.2013.10.023
26. X.O.Yang, R.Nurieva, G.J.Martinez, H.S.Kang, Y.Chung, B.P.Pappu, B.Shah, S.H.Chang, K.S.Schluns, S.S.Watowich et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29:44-56; PMID: 18585065; http://dx.doi.org/10.1016/j.immuni.2008.05.007
27. M.D.Sharma, D.-Y.Hou, B.Baban, P.A.Koni, Y.He, P.R.Chandler, B.R.Blazar, A.L.Mellor, D.H.Munn. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010; 33:942-54; PMID: 21145762; http://dx.doi.org/10.1016/j.immuni.2010.11.022
28. R.Perret, S.R.Sierro, N.K.Botelho, S.Corgnac, A.Donda, P.Romero. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 2013; 73:6597-608; PMID: 24048821; http://dx.doi.org/10.1158/0008-5472.CAN-13-0875
29. E.Sato, S.H.Olson, J.Ahn, B.Bundy, H.Nishikawa, F.Qian, A.A.Jungbluth, D.Frosina, S.Gnjatic, C.Ambrosone et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
30. + regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011; 130:645-55; PMID: 21717105; http://dx.doi.org/10.1007/s10549-011-1647-3
31. Y.Ino, R.Yamazaki-Itoh, K.Shimada, M.Iwasaki, T.Kosuge, Y.Kanai, N.Hiraoka. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013; 108:914-23; PMID: 23385730; http://dx.doi.org/10.1038/bjc.2013.32
32. C.C.Preston, M.J.Maurer, A.L.Oberg, D.W.Visscher, K.R.Kalli, L.C.Hartmann, E.L.Goode, K.L.Knutson. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE 2013; PMID: 24244610; 8:e80063; http://dx.doi.org/10.1371/journal.pone.0080063
33. M.Y.Gerner, L.M.Heltemes-Harris, B.T.Fife, M.F.Mescher. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 2013; 191:1011-5; PMID:23804712; http://dx.doi.org/10.4049/jimmunol.1300652
34. I.K.Pang, T.Ichinohe, A.Iwasaki. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza A virus. Nat Immunol 2013; 14:246-53; PMID:23314004; http://dx.doi.org/10.1038/ni.2514
35. S.Z.Ben-Sasson, A.Hogg, J.Hu-Li, P.Wingfield, X.Chen, M.Crank, S.Caucheteux, M.Ratner-Hurevich, J.A.Berzofsky, R.Nir-Paz et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 2013; 210:491-502; PMID:23460726; http://dx.doi.org/10.1084/jem.20122006
36. T.Nagato, Y.R.Lee, Y.Harabuchi, E.Celis. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res 2014; 20:1223-34; PMID:24389326; http://dx.doi.org/10.1158/1078-0432.CCR-13-2781
37. P.Antoine, V.Olislagers, A.Huygens, S.Lecomte, C.Liesnard, C.Donner, A.Marchant. Functional exhaustion of CD4+ T lymphocytes during primary cytomegalovirus infection. J Immunol 2012; 189:2665-72; PMID: 22865914; http://dx.doi.org/10.4049/jimmunol.1101165
38. S.R.Goding, K.A.Wilson, Y.Xie, K.M.Harris, A.Baxi, A.Akpinarli, A.Fulton, K.Tamada, S.E.Strome, P.A.Antony. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190:4899-909; PMID: 23536636; http://dx.doi.org/10.4049/jimmunol.1300271
39. D.-Y.Chang, S.H.Song, S.You, J.Lee, J.Kim, V.Racanelli, H.Son, E.-C.Shin. Programmed death-1 (PD-1)-dependent functional impairment of CD4(+) T cells in recurrent genital papilloma. Clin Exp Med 2013; 14(3):305-13; PMID: 23824147; http://dx.doi.org/10.1007/s10238-013-0245-6
40. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New Engl J Med 2012; 366(26):2443-54; PMID: 22658127; http://dx.doi.org/10.1056/NEJMoa1200690
41. J.R.Brahmer, S.S.Tykodi, L.Q.M.Chow, W.-J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012; 366(26):2455-65; PMID: 22658128; http://dx.doi.org/10.1056/NEJMoa1200694
42. I.Sakamaki, K.Inai, H.Tsutani. Safety of intradermal injection of monosodium urate crystals as a vaccine carrier in volunteers. Nucleos Nucleot Nucl 2011; 30:1077-84; PMID: 22132960; http://dx.doi.org/10.1080/15257770.2011.597368
43. R.J.Sylvester. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 2011; 18:113-20; PMID:21091799; http://dx.doi.org/10.1111/j.1442-2042.2010.02678.x
44. S.L.Young, M.Murphy, X.W.Zhu, P.Harnden, M.A.O'Donnell, K.James, P.M.Patel, P.J.Selby, A.M.Jackson. Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int J Cancer 2004; 112:653-60; PMID: 15382047; http://dx.doi.org/10.1002/ijc.20442
45. J.D.Fontenot, J.P.Rasmussen, M.A.Gavin, A.Y.Rudensky. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6:1142-51; PMID:16227984; http://dx.doi.org/10.1038/ni1263
46. M.J.Barnden, J.Allison, W.R.Heath, F.R.Carbone. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76:34-40; PMID:9553774; http://dx.doi.org/10.1046/j.1440-1711.1998.00709.x
47. M.W.Moore, F.R.Carbone, M.J.Bevan. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54: 777-85; PMID: 3261634; http://dx.doi.org/10.1016/S0092-8674(88)91043-4
48. A.A.Lugade, J.P.Moran, S.A.Gerber, R.C.Rose, J.G.Frelinger, E.M.Lord. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23; PMID: 15944250; http://dx.doi.org/10.4049/jimmunol.174.12.7516
49. F.J.Rich, S.Kuhn, E.J.Hyde, J.L.Harper, F.Ronchese, J.R.Kirman. Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis. Cancer Immunol Immunother 2012; 61(12):2333-42; PMID: 22714285; http://dx.doi.org/10.1007/s00262-012-1291-8
50. J.Z.-I.Ma, S.N.Lim, J.S.Qin, J.Yang, N.Enomoto, C.Ruedl, F.Ronchese. Murine CD4+ T cell responses are inhibited by cytotoxic T cell-mediated killing of dendritic cells and are restored by antigen transfer. PLoS ONE 2012; 7:e37481; PMID: 22649530; http://dx.doi.org/10.1371/journal.pone.0037481